BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 20,500 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 20,500 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $96.31, for a total value of $1,974,355.00. Following the completion of the transaction, the chief executive officer directly owned 688,209 shares of the company’s stock, valued at $66,281,408.79. This represents a 2.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Trading Up 0.3%

NASDAQ BNTX traded up $0.33 on Friday, hitting $96.73. The company’s stock had a trading volume of 1,176,224 shares, compared to its average volume of 1,110,613. The company’s 50-day moving average is $97.00 and its 200 day moving average is $95.37. The firm has a market cap of $24.46 billion, a PE ratio of -12.35 and a beta of 1.29. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The business had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.BioNTech’s revenue for the quarter was down 59.5% on a year-over-year basis. During the same quarter last year, the firm posted ($1.60) EPS. As a group, analysts predict that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on BNTX shares. UBS Group raised BioNTech from a “neutral” rating to a “buy” rating and increased their price target for the company from $117.00 to $135.00 in a research note on Wednesday, May 27th. Canaccord Genuity Group cut their price objective on BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research note on Monday, August 31st. Wall Street Zen cut BioNTech from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Morgan Stanley decreased their target price on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research report on Wednesday, July 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BioNTech currently has an average rating of “Moderate Buy” and a consensus price target of $126.00.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC boosted its position in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares in the last quarter. EFG International AG bought a new stake in BioNTech in the fourth quarter worth approximately $29,000. Caitong International Asset Management Co. Ltd increased its holdings in BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock worth $30,000 after purchasing an additional 260 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in BioNTech in the second quarter valued at approximately $39,000. Finally, Tower Research Capital LLC TRC lifted its stake in BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after buying an additional 305 shares during the period. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.